Literature DB >> 19477428

A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.

Anurag Singh1, Patricia Greninger, Daniel Rhodes, Louise Koopman, Sheila Violette, Nabeel Bardeesy, Jeff Settleman.   

Abstract

K-ras mutations occur frequently in epithelial cancers. Using short hairpin RNAs to deplete K-Ras in lung and pancreatic cancer cell lines harboring K-ras mutations, two classes were identified-lines that do or do not require K-Ras to maintain viability. Comparing these two classes of cancer cells revealed a gene expression signature in K-Ras-dependent cells, associated with a well-differentiated epithelial phenotype, which was also seen in primary tumors. Several of these genes encode pharmacologically tractable proteins, such as Syk and Ron kinases and integrin beta6, depletion of which induces epithelial-mesenchymal transformation (EMT) and apoptosis specifically in K-Ras-dependent cells. These findings indicate that epithelial differentiation and tumor cell viability are associated, and that EMT regulators in "K-Ras-addicted" cancers represent candidate therapeutic targets.

Entities:  

Mesh:

Year:  2009        PMID: 19477428      PMCID: PMC2743093          DOI: 10.1016/j.ccr.2009.03.022

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  44 in total

1.  R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.

Authors:  Sylvia Braselmann; Vanessa Taylor; Haoran Zhao; Su Wang; Catherine Sylvain; Muhammad Baluom; Kunbin Qu; Ellen Herlaar; Angela Lau; Chi Young; Brian R Wong; Scott Lovell; Thomas Sun; Gary Park; Ankush Argade; Stipo Jurcevic; Polly Pine; Rajinder Singh; Elliott B Grossbard; Donald G Payan; Esteban S Masuda
Journal:  J Pharmacol Exp Ther       Date:  2006-08-31       Impact factor: 4.030

Review 2.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

3.  Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.

Authors:  Christopher D Coldren; Barbara A Helfrich; Samir E Witta; Michio Sugita; Razvan Lapadat; Chan Zeng; Anna Barón; Wilbur A Franklin; Fred R Hirsch; Mark W Geraci; Paul A Bunn
Journal:  Mol Cancer Res       Date:  2006-08       Impact factor: 5.852

Review 4.  Src, chemoresistance and epithelial to mesenchymal transition: are they related?

Authors:  Ami N Shah; Gary E Gallick
Journal:  Anticancer Drugs       Date:  2007-04       Impact factor: 2.248

Review 5.  Epidermal growth factor receptor mutations in lung cancer.

Authors:  Sreenath V Sharma; Daphne W Bell; Jeffrey Settleman; Daniel A Haber
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

6.  Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

Authors:  Klaus W Wagner; Elizabeth A Punnoose; Thomas Januario; David A Lawrence; Robert M Pitti; Kate Lancaster; Dori Lee; Melissa von Goetz; Sharon Fong Yee; Klara Totpal; Ling Huw; Viswanatham Katta; Guy Cavet; Sarah G Hymowitz; Lukas Amler; Avi Ashkenazi
Journal:  Nat Med       Date:  2007-09-02       Impact factor: 53.440

7.  Characterizing the cancer genome in lung adenocarcinoma.

Authors:  Barbara A Weir; Michele S Woo; Gad Getz; Sven Perner; Li Ding; Rameen Beroukhim; William M Lin; Michael A Province; Aldi Kraja; Laura A Johnson; Kinjal Shah; Mitsuo Sato; Roman K Thomas; Justine A Barletta; Ingrid B Borecki; Stephen Broderick; Andrew C Chang; Derek Y Chiang; Lucian R Chirieac; Jeonghee Cho; Yoshitaka Fujii; Adi F Gazdar; Thomas Giordano; Heidi Greulich; Megan Hanna; Bruce E Johnson; Mark G Kris; Alex Lash; Ling Lin; Neal Lindeman; Elaine R Mardis; John D McPherson; John D Minna; Margaret B Morgan; Mark Nadel; Mark B Orringer; John R Osborne; Brad Ozenberger; Alex H Ramos; James Robinson; Jack A Roth; Valerie Rusch; Hidefumi Sasaki; Frances Shepherd; Carrie Sougnez; Margaret R Spitz; Ming-Sound Tsao; David Twomey; Roel G W Verhaak; George M Weinstock; David A Wheeler; Wendy Winckler; Akihiko Yoshizawa; Soyoung Yu; Maureen F Zakowski; Qunyuan Zhang; David G Beer; Ignacio I Wistuba; Mark A Watson; Levi A Garraway; Marc Ladanyi; William D Travis; William Pao; Mark A Rubin; Stacey B Gabriel; Richard A Gibbs; Harold E Varmus; Richard K Wilson; Eric S Lander; Matthew Meyerson
Journal:  Nature       Date:  2007-11-04       Impact factor: 49.962

8.  Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition.

Authors:  Victor D Acevedo; Rama D Gangula; Kevin W Freeman; Rile Li; Youngyou Zhang; Fen Wang; Gustavo E Ayala; Leif E Peterson; Michael Ittmann; David M Spencer
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

Review 9.  Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.

Authors:  Yi Lu; Hang-Ping Yao; Ming-Hai Wang
Journal:  Cancer Lett       Date:  2007-09-21       Impact factor: 8.679

10.  Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains.

Authors:  Edward T Olejniczak; Charles Van Sant; Mark G Anderson; Gang Wang; Stephen K Tahir; Guido Sauter; Rick Lesniewski; Dimitri Semizarov
Journal:  Mol Cancer Res       Date:  2007-04       Impact factor: 5.852

View more
  406 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.

Authors:  Rafael B Blasco; Sarah Francoz; David Santamaría; Marta Cañamero; Pierre Dubus; Jean Charron; Manuela Baccarini; Mariano Barbacid
Journal:  Cancer Cell       Date:  2011-04-21       Impact factor: 31.743

3.  The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins.

Authors:  Anchal Chandra; Hernán E Grecco; Venkat Pisupati; David Perera; Liam Cassidy; Ferdinandos Skoulidis; Shehab A Ismail; Christian Hedberg; Michael Hanzal-Bayer; Ashok R Venkitaraman; Alfred Wittinghofer; Philippe I H Bastiaens
Journal:  Nat Cell Biol       Date:  2011-12-18       Impact factor: 28.824

Review 4.  Identification of aberrant pathways and network activities from high-throughput data.

Authors:  Jinlian Wang; Yuji Zhang; Catalin Marian; Habtom W Ressom
Journal:  Brief Bioinform       Date:  2012-01-27       Impact factor: 11.622

5.  S-Farnesyl-Thiopropionic Acid (FTPA) Triazoles as Potent Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase.

Authors:  Joel A Bergman; Kalub Hahne; Jiao Song; Christine A Hrycyna; Richard A Gibbs
Journal:  ACS Med Chem Lett       Date:  2011-11-28       Impact factor: 4.345

Review 6.  The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer?

Authors:  Simone Brabletz; Thomas Brabletz
Journal:  EMBO Rep       Date:  2010-08-13       Impact factor: 8.807

7.  A systems biology approach to personalizing therapeutic combinations.

Authors:  Lawrence N Kwong; Timothy P Heffernan; Lynda Chin
Journal:  Cancer Discov       Date:  2013-12       Impact factor: 39.397

8.  FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Authors:  Murry W Wynes; Trista K Hinz; Dexiang Gao; Michael Martini; Lindsay A Marek; Kathryn E Ware; Michael G Edwards; Diana Böhm; Sven Perner; Barbara A Helfrich; Rafal Dziadziuszko; Jacek Jassem; Szymon Wojtylak; Aleksandra Sejda; Joseph M Gozgit; Paul A Bunn; D Ross Camidge; Aik-Choon Tan; Fred R Hirsch; Lynn E Heasley
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

9.  KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.

Authors:  Alexandros Tzatsos; Polina Paskaleva; Francesco Ferrari; Vikram Deshpande; Svetlana Stoykova; Gianmarco Contino; Kwok-Kin Wong; Fei Lan; Patrick Trojer; Peter J Park; Nabeel Bardeesy
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

10.  Depletion of K-Ras promotes proteasome degradation of survivin.

Authors:  Awet Tecleab; Saïd M Sebti
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.